相关实验视频
Updated: Jun 14, 2025

08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.0K
加拿大的JAK抑制剂的全国和省际处方模式:一次重复的横截面分析
Katherine C Saunders1, Ahmad Shakeri1,2, Cherry Chu2
1Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada.
Clinical rheumatology
|August 28, 2024
概括
在加拿大,从2016年到2022年,Janus 激酶 (JAK) 抑制剂的使用量在加拿大增加. 各省的发行率各不相同,这凸显了对JAK抑制剂处方实践的进一步研究的需要.
科学领域:
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
- 医疗保健服务研究 医疗服务研究
背景情况:
- 简氏激酶 (JAK) 抑制剂代表了针对免疫媒介疾病的新型治疗类.
- 了解JAK抑制剂的使用模式至关重要,特别是考虑到安全问题及其对处方的影响.
- 有限的数据存在于加拿大的JAK抑制剂的现实世界使用.
研究的目的:
- 描述加拿大的JAK抑制剂的全国和省级利用情况.
- 分析从2016年到2022年发放JAK抑制剂的趋势.
- 为了确定加拿大各省使用JAK抑制剂的差异.
主要方法:
- 采用了一种重复的横截面研究设计.
- 在零售药店分发的JAK抑制剂单位 (托法西提尼布,鲁克索利提尼布,巴里西提尼布,乌帕达西提尼布) 的数据来自IQVIA的Compuscript数据库.
- 研究期间涵盖2016年7月1日至2022年6月30日,涵盖了加拿大所有十个省份.
主要成果:
- 据估计,在2016年至2022年期间,全国共分发了26,126,409个JAK抑制剂单位,平均每10万人分发9,431个单位.
- 在研究期间,所有省份的分发率都增加了.
- 托法西提尼布是最常用的JAK抑制剂 (76%),其次是鲁克索利提尼布 (16%),乌帕达西提尼布 (7.9%) 和巴里西提尼布 (1.1%).
结论:
- 在加拿大,在国家和省级,JAK抑制剂的使用量明显增加.
- 在各省份的JAK抑制剂发行率中存在显著的变化,这表明药物覆盖范围,疾病患病率和处方习惯的潜在影响.
- 需要进一步调查,以了解推动省区差异的因素,并确保适当使用JAK抑制剂.
关键词:
巴里西提尼布 (Baricitinib) 是一种药物.加拿大 加拿大 加拿大 加拿大 加拿大雅克-抑制剂的使用规定模式的规定模式卢克索利提尼布 (Ruxolitinib) 是一种药物.托法西提尼布 (tofacitinib) 是一种可怕的药物.在Upadacitinib上使用.更多相关视频
相关概念视频
Analysis of Population Pharmacokinetic Data
240
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
240
The JAK-STAT Signaling Pathway
8.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.7K
Pharmacovigilance
789
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
789
Prescription, Nonprescription and Orphan Drugs
706
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
706
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
51
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
51
Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K

